| Patient | Ernest Hemingway |
|---|---|
| Date of birth | 1970-07-21 |
| Identifiers | MRN HR-ET003-SYN; SSN (made up) 000-03-7419 |
| Document date | 2026-04-13 |
| Author | Walter Brandt-Ochoa, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review: phlebotomy, drinking, mood and liver MRI. [S]
Mr. Hemingway returns six weeks after intake. He has had three weekly phlebotomies without dizziness, and the fourth is planned after today's blood tests. His MRI this morning has been reported. He is drinking three or four drinks a day, all in the evening, with naltrexone daily; his AUDIT-C for the past month is 7. He has had no tremor or sweats. His mood is a little better but he still wakes early and finds it hard to start writing; his PHQ-9 is 13. Sertraline 50 mg causes no side effects. Home blood pressure averages 136/84. Headaches are about twice a week. His guns remain at the club. The echocardiogram ordered at intake has not been scheduled yet. [S]
| Element | Detail |
|---|---|
| Phlebotomy | Three sessions; the fourth today |
| Alcohol | Three or four drinks a day, evenings only; AUDIT-C 7 |
| Mood | PHQ-9 13; item 9 scored 0 |
| Home blood pressure | Average 136/84 |
| MRI of the liver | Liver iron about 9.8 mg/g; stiffness 3.1 kPa; no lesion |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No dizziness after phlebotomy; tiredness a little better |
| Gastrointestinal | Negative | No abdominal pain, nausea or jaundice |
| Neurological | Positive | Headaches about twice a week; no tremor |
| Psychiatric | Positive | Early waking and low drive in the mornings; no thoughts of suicide or wishes to be dead since the last visit |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naltrexone 50 mg oral tablet, one tablet daily, to reduce heavy drinking | One tablet daily | Oral route | 2026-03-02 | active | S |
| Thiamine 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-08-31 | completed | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-04-13 | completed | S |
| Sertraline 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-04-13 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-06-08 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-13 | Body height | 183 | cm | S |
| 2026-04-13 | Body weight | 96.2 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 28.7 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 80 | /min | S |
| 2026-04-13 | Respiratory rate | 16 | /min | S |
| 2026-04-13 | Body temperature | 36.6 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-13 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-04-13 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 99 | fL | 80-100 fL | Normal | S |
| 2026-04-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 | U/L | 10-40 U/L | High | S |
| 2026-04-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 49 | U/L | 7-55 U/L | Normal | S |
| 2026-04-13 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 104 | U/L | 8-61 U/L | High | S |
| 2026-04-13 | Ferritin [Mass/volume] in Serum or Plasma | 1180 | ng/mL | 24-336 ng/mL | High | S |
| 2026-04-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 13 | {score} | S | ||
| 2026-04-13 | Total score [AUDIT-C] | 7 | {score} | S |
Vital signs recorded on 2026-04-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 138/86, pulse 80; weight 96.2 kg |
| Cardiovascular | Regular rhythm; no murmur |
| Abdomen | Liver edge just palpable, smooth; no spleen felt |
| Neurological | No tremor |
| Psychiatric | Engaged; mood low but brighter; no psychotic features |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Alcohol use disorder, severe; heavy daily drinking for most of his adult life; synthetic modern episode linked to his documented heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding of DSM-5-TR severe alcohol use disorder (seven criteria); person-first language; not a claim about his real diagnosis. |
| Raised transferrin saturation and ferritin found on routine intake tests, cause not yet known (heavy drinking, liver disease or iron overload) | resolved | confirmed | R79.0 | S — Synthetic presenting finding; superseded when HFE testing gave the diagnosis. |
| Hereditary hemochromatosis, HFE C282Y homozygous, with iron overload (ferritin over 1,000 ng/mL) and no advanced liver fibrosis on imaging | active | confirmed | E83.110 | S — Synthetic modern diagnosis. Whether he had hemochromatosis is disputed (CLM-0013); the modern diagnosis is not offered as proof of it. |
| Major depressive disorder, single episode, moderate; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed | F32.1 | S — Synthetic modern diagnosis; not a claim about his real mood. The roster's bipolar disorder lead is disputed (CLM-0014) and is not used. |
| Essential hypertension, stage 2, with heavy drinking contributing | active | confirmed | I10 | S — Synthetic modern diagnosis confirmed by home readings. |
| Post-concussion symptoms (headaches, slowed thinking and forgetfulness) after repeated head injuries, most recently a concussion with a skull fracture a year ago; chronic traumatic encephalopathy is not diagnosed | active | confirmed | F07.81 | S — Synthetic modern diagnosis anchored to his documented head injuries; alcohol and depression also affect the symptoms. |
| Prediabetes (HbA1c 6.1%) | active | confirmed | R73.03 | S — Synthetic finding on diabetes screening; iron overload and alcohol both raise the risk of diabetes. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin before each phlebotomy (hold if under 12.0 g/dL) | Before every session; full blood count at visits | Completed today | Hemoglobin 14.2 g/dL, MCV 99 fL; all pre-session checks above 13.5 |
| Laboratory | Serum ferritin during induction phlebotomy | At diagnosis, then about every 10 to 12 phlebotomies; target 50 to 100 ng/mL | Completed today | Ferritin 1,180 ng/mL after three sessions |
| Medication safety | Weekly phlebotomy of 500 mL | Weekly during induction | Completed today | Three sessions; the fourth today |
| Imaging | Liver fibrosis staging (ferritin over 1,000 ng/mL and raised ALT) | Once at diagnosis: elastography, MRI or biopsy | Completed today | MRI today: liver iron about 9.8 mg Fe/g; stiffness 3.1 kPa, mild fibrosis; no advanced fibrosis; no lesion |
| Imaging | Liver cancer surveillance | Every six months only with cirrhosis or advanced fibrosis | Not indicated | No cirrhosis or advanced fibrosis on MRI |
| Self-management | Diet: no iron or vitamin C supplements, no raw shellfish | Every visit | Completed today | No supplements; no raw shellfish |
| Laboratory | Liver tests on naltrexone | Baseline, about one month, then every three to six months | Completed today | AST 41, ALT 49 and GGT 104 U/L at six weeks on naltrexone |
| Survey | Drinking quantity and goal (AUDIT-C, drinking diary) | Every visit | Completed today | AUDIT-C 7; three or four drinks a day; he chose to stop within the month |
| Medication safety | Opioid use and pain plan on naltrexone | Every visit | Completed today | No opioids |
| Examination | Alcohol withdrawal risk and symptoms when cutting down or stopping | Each visit while cutting down | Completed today | No withdrawal signs; one drink fewer every week or so planned |
| Self-management | Psychosocial support for alcohol use | Offer at each stage | Completed today | Mutual-help group and alcohol counseling offered; he chose to work on drinking in weekly therapy |
| Medication safety | Thiamine | Daily while drinking heavily | Completed today | Taking thiamine daily |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Completed today | PHQ-9 13, item 9 scored 0; partial response |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | No side effects; increased to 100 mg; the behavioral health clinician checks side effects at therapy in two weeks |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; firearms remain off-site |
| Self-management | Psychotherapy (CBT) | Weekly | Completed today | Five sessions so far |
| Examination | Blood pressure, home readings, weight and cardiac auscultation | Every visit | Completed today | 138/86 in clinic; home average 136/84; weight 96.2 kg |
| Imaging | Echocardiogram | At diagnosis of stage 2 hypertension | Ordered | Ordered at intake; not yet scheduled; the clinic will follow it up |
| Examination | Post-concussion symptoms (headache frequency, sleep, concentration) | Every visit | Completed today | Headaches about twice a week |
Goal progress:
Guideline basis: Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases (2011); ACG Clinical Guideline: Hereditary Hemochromatosis (2019); The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and depression, bipolar, and mood disorders monographs (2026)
Follow-up: Weekly phlebotomy. Fourteen-week review in eight weeks with blood count, ferritin, liver tests, PHQ-9 and AUDIT-C. Weekly psychotherapy. Next scheduled visit 2026-06-08: fourteen-week review: phlebotomy, the decision to stop drinking, mood and blood pressure. [S]